These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 35596584)

  • 1. Epidemiology, Survival, and Clinical Characteristics of Inclusion Body Myositis.
    Lindgren U; Pullerits R; Lindberg C; Oldfors A
    Ann Neurol; 2022 Aug; 92(2):201-212. PubMed ID: 35596584
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cytosolic 5'-nucleotidase 1A autoantibody profile and clinical characteristics in inclusion body myositis.
    Lilleker JB; Rietveld A; Pye SR; Mariampillai K; Benveniste O; Peeters MT; Miller JA; Hanna MG; Machado PM; Parton MJ; Gheorghe KR; Badrising UA; Lundberg IE; Sacconi S; Herbert MK; McHugh NJ; Lecky BR; Brierley C; Hilton-Jones D; Lamb JA; Roberts ME; Cooper RG; Saris CG; Pruijn GJ; Chinoy H; van Engelen BG;
    Ann Rheum Dis; 2017 May; 76(5):862-868. PubMed ID: 28122761
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Diagnostic Accuracy of Anti-CN1A on the Diagnosis of Inclusion Body Myositis. A Hierarchical Bivariate and Bayesian Meta-analysis.
    Mavroudis I; Knights M; Petridis F; Chatzikonstantinou S; Karantali E; Kazis D
    J Clin Neuromuscul Dis; 2021 Sep; 23(1):31-38. PubMed ID: 34431799
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pathogenic role of anti-cN1A autoantibodies in sporadic inclusion body myositis.
    Yamashita S; Tawara N; Zhang Z; Nakane S; Sugie K; Suzuki N; Nishino I; Aoki M
    J Neurol Neurosurg Psychiatry; 2023 Dec; 94(12):1018-1024. PubMed ID: 37451693
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Update in inclusion body myositis.
    Machado P; Brady S; Hanna MG
    Curr Opin Rheumatol; 2013 Nov; 25(6):763-71. PubMed ID: 24067381
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of sex, age at onset, and anti-cN1A antibodies on sporadic inclusion body myositis.
    Yamashita S; Tawara N; Sugie K; Suzuki N; Nishino I; Aoki M
    J Neurol Sci; 2024 Sep; 464():123164. PubMed ID: 39126732
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Atypical presentations of inclusion body myositis: Clinical characteristics and long-term outcomes.
    Alamr M; Pinto MV; Naddaf E
    Muscle Nerve; 2022 Dec; 66(6):686-693. PubMed ID: 36052422
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inclusion Body Myositis With Dysphagia Diagnosed Using Pharyngoesophageal High-Resolution Manometry.
    Chiba T
    ACG Case Rep J; 2022 Aug; 9(8):e00850. PubMed ID: 36061244
    [No Abstract]   [Full Text] [Related]  

  • 9. Exploring challenges in the management and treatment of inclusion body myositis.
    Skolka MP; Naddaf E
    Curr Opin Rheumatol; 2023 Nov; 35(6):404-413. PubMed ID: 37503813
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical Subgroups and Factors Associated With Progression in Patients With Inclusion Body Myositis.
    Michelle EH; Pinal-Fernandez I; Casal-Dominguez M; Albayda J; Paik JJ; Tiniakou E; Adler B; Mecoli CA; Danoff SK; Christopher-Stine L; Mammen AL; Lloyd TE
    Neurology; 2023 Mar; 100(13):e1406-e1417. PubMed ID: 36690456
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inclusion body myositis: evolving concepts.
    Perez-Rosendahl M; Mozaffar T
    Curr Opin Neurol; 2022 Oct; 35(5):604-610. PubMed ID: 36069417
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inclusion Body Myositis and Neoplasia: A Narrative Review.
    Damian L; Login CC; Solomon C; Belizna C; Encica S; Urian L; Jurcut C; Stancu B; Vulturar R
    Int J Mol Sci; 2022 Jul; 23(13):. PubMed ID: 35806366
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tendon Transfers to Improve Grip and Pinch in Patients with Sporadic Inclusion Body Myositis.
    Hua C; Bhai S; Cheng J; Hinojosa J; Wilson L; Lubinus M; Bhashyam AR
    Plast Reconstr Surg Glob Open; 2023 Nov; 11(11):e5418. PubMed ID: 38025613
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost of illness in inclusion body myositis: results from a cross-sectional study in Germany.
    Senn KC; Thiele S; Kummer K; Walter MC; Nagels KH
    Orphanet J Rare Dis; 2023 Oct; 18(1):337. PubMed ID: 37880781
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The spectrum of idiopathic inflammatory myopathies in Western Australia: epidemiological characteristics and mortality over time.
    Nossent J; Keen H; Preen DB; Inderjeeth CA
    Rheumatol Int; 2024 Feb; 44(2):329-337. PubMed ID: 37819456
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Epidemiology of the idiopathic inflammatory myopathies.
    Khoo T; Lilleker JB; Thong BY; Leclair V; Lamb JA; Chinoy H
    Nat Rev Rheumatol; 2023 Nov; 19(11):695-712. PubMed ID: 37803078
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inclusion body myositis with early onset: a population-based study.
    Lindgren U; Hedberg-Oldfors C; Pullerits R; Lindberg C; Oldfors A
    J Neurol; 2023 Nov; 270(11):5483-5492. PubMed ID: 37498322
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Myositis interstitial lung disease and autoantibodies.
    Chaudhry S; Christopher-Stine L
    Front Med (Lausanne); 2023; 10():1117071. PubMed ID: 37384043
    [TBL] [Abstract][Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.